TORONTO, April 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and progress at the following upcoming conferences:
Investor Conferences:
H.C. Wainwright Global Life Sciences Conference
Presenter: Dr. Niclas Stiernholm, Chief Executive Officer
Date and Time: April 9, 2019 at 3:10 p.m. BST
Location: Grosvenor House, London
18th Annual Needham Healthcare Conference
Presenter: Dr. Bob Uger, Chief Scientific Officer
Date and Time: April 10, 2019 at 12:00 p.m. ET
Location: Westin Grand Central Hotel, New York City
A live audio webcast of the H.C. Wainwright Global Life Sciences Conference presentation will be available under the investor relations section of Trillium's website at www.trilliumtherapeutics.com.
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a "do not eat" signal that cancer cells frequently use to evade the immune system. Trillium also has a preclinical STING program and a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets.
For more information, visit: www.trilliumtherapeutics.com
Contact and Investor Relations:
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com
Media Relations:
Jessica Tieszen
Canale Communications for Trillium Therapeutics
619-849-5385
jessica@canalecomm.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
